Background
Several OPS licensees shared concerns regarding psilocybin products with high psilocin content being used for lower dose administration sessions.
In response to this concern, OPS convened a Psilocybin Product Potency Workgroup meeting in March, 2026.
All licensed psilocybin manufacturers and laboratories were invited to participate and there was a public comment period to receive input from members of the public, including other licensees. Oregon Environmental Laboratory Accreditation Program (ORELAP) also participated.
The purpose of the workgroup was to consider potency formulas for psilocybin products, including “total psilocybin equivalent", and identify safety issues related to the use of high-psilocin products. The workgroup was originally scheduled to meet twice in March, however OPS and ORELAP concluded that a second meeting was unlikley to result in further productive conversation. An audio recording of the March 3rd meeting can be accessed below. Workgroup members are invited to continue sharing relevant high-quality peer reviewed research that addresses psilocin to psilocybin ratio, or other values that represent unsafe thresholds for subperceptual doses.
This workgroup was not a part of a rulemaking process, but may inform
OPS rulemaking in 2026.
Psilocybin Product Potency Workgroup Meeting
Psilocybin Meeting Calendar
Listening - Current Year
Documents
Listening Sessions